Published in Mol Pharmacol on December 01, 1988
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
The mechanism of Mus81-Mms4 cleavage site selection distinguishes it from the homologous endonuclease Rad1-Rad10. Mol Cell Biol (2003) 2.59
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol (2000) 2.41
Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol (2006) 2.16
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov (2011) 1.80
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci U S A (1995) 1.50
The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res (1989) 1.49
Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res (1991) 1.47
Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. Proc Natl Acad Sci U S A (1989) 1.45
Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol (1996) 1.44
Yeast glycosylation mutants are sensitive to aminoglycosides. Proc Natl Acad Sci U S A (1995) 1.39
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol (2011) 1.36
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc Natl Acad Sci U S A (1994) 1.34
Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.32
Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem (2012) 1.26
SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc Natl Acad Sci U S A (1995) 1.21
A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II. Mol Cell Biol (1991) 1.20
Global fitness profiling of fission yeast deletion strains by barcode sequencing. Genome Biol (2010) 1.19
Specific biomarkers for stochastic division patterns and starvation-induced quiescence under limited glucose levels in fission yeast. FEBS J (2011) 1.15
DNA repair functions that control sensitivity to topoisomerase-targeting drugs. Eukaryot Cell (2004) 1.15
A novel mutation in DNA topoisomerase I of yeast causes DNA damage and RAD9-dependent cell cycle arrest. Genetics (1993) 1.14
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol (2013) 1.10
Accelerating the discovery of biologically active small molecules using a high-throughput yeast halo assay. J Nat Prod (2007) 1.10
Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proc Natl Acad Sci U S A (2008) 1.07
Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. Genetics (1996) 1.06
Repair of topoisomerase-mediated DNA damage in bacteriophage T4. Genetics (2001) 1.06
Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat (2011) 1.00
Pancreatic β-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One (2011) 0.99
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer (1997) 0.98
An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo. Mol Cell Biol (2000) 0.97
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother (1999) 0.90
Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol (1994) 0.87
Template topology and transcription: chromatin templates relaxed by localized linearization are transcriptionally active in yeast. Mol Cell Biol (1997) 0.87
Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani. Antimicrob Agents Chemother (2005) 0.87
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol (1997) 0.87
Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans. Antimicrob Agents Chemother (1995) 0.85
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones. Nucleic Acids Res (1992) 0.82
Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin. Cancer Chemother Pharmacol (1994) 0.82
Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae. Mol Genet Genomics (2004) 0.82
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer (1996) 0.79
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer (2016) 0.79
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer (1999) 0.79
Topoisomerase I inhibitors and drug resistance. Cytotechnology (1998) 0.78
Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I. PLoS One (2014) 0.78
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. Br J Cancer (2004) 0.77
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br J Cancer (1990) 0.77
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorg Med Chem Lett (2009) 0.76
Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. Org Biomol Chem (2016) 0.76
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. Invest New Drugs (2004) 0.76
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs (2005) 0.75
The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc Natl Acad Sci U S A (1991) 15.52
The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A (2000) 7.92
Characterization of a "silencer" in yeast: a DNA sequence with properties opposite to those of a transcriptional enhancer. Cell (1985) 6.23
Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell (1982) 6.11
DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A (1984) 5.75
Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system. Mol Cell Biol (1995) 5.71
Studies on the mechanism of action of nalidixic acid. Antimicrob Agents Chemother (1973) 5.64
Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition. Proc Natl Acad Sci U S A (1981) 5.60
Elimination of false positives that arise in using the two-hybrid system. Biotechniques (1993) 5.06
The two-hybrid system: an assay for protein-protein interactions. Trends Genet (1994) 5.06
Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J (1989) 4.08
Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci U S A (2000) 3.94
Perinuclear localization of chromatin facilitates transcriptional silencing. Nature (1998) 3.68
Crystal structure of a SIR2 homolog-NAD complex. Cell (2001) 3.57
Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (1987) 3.56
Role of interactions between the origin recognition complex and SIR1 in transcriptional silencing. Nature (1996) 3.26
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants. Cell (1988) 3.22
Targeting of SIR1 protein establishes transcriptional silencing at HM loci and telomeres in yeast. Cell (1993) 2.91
The something about silencing protein, Sas3, is the catalytic subunit of NuA3, a yTAF(II)30-containing HAT complex that interacts with the Spt16 subunit of the yeast CP (Cdc68/Pob3)-FACT complex. Genes Dev (2000) 2.77
Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene. Proc Natl Acad Sci U S A (1985) 2.75
Human homologues of yeast helicase. Nature (1996) 2.71
Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun (2000) 2.65
Two new S-phase-specific genes from Saccharomyces cerevisiae. Yeast (1997) 2.64
Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med (1983) 2.63
Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem (1995) 2.62
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol (1993) 2.40
NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene (2007) 2.29
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ (1991) 2.20
A novel Golgi membrane protein is part of a GTPase-binding protein complex involved in vesicle targeting. EMBO J (2000) 2.17
Ionization and divalent cation dissociation constants of nalidixic and oxolinic acids. Bioinorg Chem (1978) 2.09
Yeast ASF1 protein is required for cell cycle regulation of histone gene transcription. Genetics (2001) 2.08
Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J Biol Chem (1984) 2.07
Recent excitement in the DNA replication problem. Nature (1977) 2.05
Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J Biol Chem (1994) 2.04
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
The SIR1 gene of Saccharomyces cerevisiae and its role as an extragenic suppressor of several mating-defective mutants. Mol Cell Biol (1991) 1.99
PNG1, a yeast gene encoding a highly conserved peptide:N-glycanase. J Cell Biol (2000) 1.98
Structure of the histone acetyltransferase Hat1: a paradigm for the GCN5-related N-acetyltransferase superfamily. Cell (1998) 1.96
In-person vs telephone-administered multiple-pass 24-hour recalls in women: validation with doubly labeled water. J Am Diet Assoc (2000) 1.93
Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res (1979) 1.93
Bacteriophage T7 lysozyme is an N-acetylmuramyl-L-alanine amidase. J Biol Chem (1973) 1.92
A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. Science (1998) 1.86
Topoisomerases and yeast rRNA transcription: negative supercoiling stimulates initiation and topoisomerase activity is required for elongation. Genes Dev (1992) 1.84
Signal-mediated import of bacteriophage T7 RNA polymerase into the Saccharomyces cerevisiae nucleus and specific transcription of target genes. Mol Cell Biol (1990) 1.84
Targeting of the yeast Ty5 retrotransposon to silent chromatin is mediated by interactions between integrase and Sir4p. Mol Cell Biol (2001) 1.81
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res (1980) 1.78
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Crystal structure of the histone acetyltransferase Hpa2: A tetrameric member of the Gcn5-related N-acetyltransferase superfamily. J Mol Biol (1999) 1.70
Identification and characterization of yeast mutants and the gene for a cruciform cutting endonuclease. EMBO J (1992) 1.69
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Longitudinal changes in fatness in white children: no effect of childhood energy expenditure. Am J Clin Nutr (1998) 1.64
A novel form of transcriptional silencing by Sum1-1 requires Hst1 and the origin recognition complex. Mol Cell Biol (2001) 1.64
Influence of body composition on the accuracy of reported energy intake in children. Obes Res (2000) 1.59
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem (1989) 1.57
The yeast SAS (something about silencing) protein complex contains a MYST-type putative acetyltransferase and functions with chromatin assembly factor ASF1. Genes Dev (2001) 1.52
Identification of two RNA-binding proteins associated with human telomerase RNA. Mol Biol Cell (2000) 1.50
Gene expression. Chromatin contract to silence. Nature (1990) 1.50
Reduced expression of the isoleucine and valine enzymes in integration host factor mutants of Escherichia coli. J Mol Biol (1984) 1.45
Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues. J Med Chem (1989) 1.43
Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer (1977) 1.39
Diaminobenzidine as a myelin stain in semithin plastic sections. Biotech Histochem (1999) 1.38
Identification and characterization of the genes for two topoisomerase I-interacting proteins from Saccharomyces cerevisiae. Yeast (1999) 1.32
Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep (1978) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Cross-finger pedicle flaps in the hand. J Bone Joint Surg Am (1971) 1.29
Developmental changes in energy expenditure and physical activity in children: evidence for a decline in physical activity in girls before puberty. Pediatrics (1998) 1.28
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem (1991) 1.28
Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. Biochem Pharmacol (1978) 1.26
Identification of quantitative trait loci affecting reproduction in pigs. J Anim Sci (2001) 1.24
Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. J Biol Chem (1989) 1.20
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst (1989) 1.19
Anatomical course of the thenar branch of the median nerve--usually in a separate tunnel through the transverse carpal ligament. J Bone Joint Surg Am (1970) 1.19
Plakortides, novel cyclic peroxides from the sponge Plakortis halichondrioides: activators of cardiac SR-CA(2+)-pumping ATPase. J Nat Prod (1996) 1.17
Two separate conserved domains of eukaryotic DNA topoisomerase I bind to each other and reconstitute enzymatic activity. Chromosoma (1998) 1.16
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. Cancer Res (1976) 1.16
In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep (1978) 1.15
Effect of nalidixic acid on the growth of deoxyribonucleic acid bacteriophages. J Virol (1972) 1.14
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Origin of the residual transforming activity of denatured Bacillus subtilis DNA. J Mol Biol (1968) 1.09
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res (1987) 1.09
The role of DNA replication in the repression of the yeast mating-type silent loci. Cold Spring Harb Symp Quant Biol (1984) 1.08
Conditional-lethal deoxyribonucleic acid ligase mutant of Escherichia coli. J Bacteriol (1979) 1.08
Mutations in GCR3, a gene involved in the expression of glycolytic genes in Saccharomyces cerevisiae, suppress the temperature-sensitive growth of hpr1 mutants. Genetics (1996) 1.08
The pronator quadratus in motions and in stabilization of the radius and ulna at the distal radioulnar joint. J Hand Surg Am (1976) 1.08
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res (1989) 1.08
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res (1985) 1.07
Fat intake and adiposity in children of lean and obese parents. Am J Clin Nutr (1996) 1.06
Biological responses to porcine respiratory and reproductive syndrome virus in pigs of two genetic populations. J Anim Sci (2005) 1.05
Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol (2001) 1.05
Differential immunity in pigs with high and low responses to porcine reproductive and respiratory syndrome virus infection. J Anim Sci (2007) 1.04
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol (1990) 1.03